SDC1: Syndecan-1
Cell surface proteoglycan that contains both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on SDC1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Indatuximab ravtansine | Phase 2 | Biotest | Antibody-drug conjugate | Binding agentSyndecan-1 binding agent | 0 |
- COVID-190.57
- Dengue disease0.48
- Bladder calculus0.42
- Osteoarthritis, knee0.36
- Hyperlipidemia0.33
- Metabolic disease0.33
- Osteoarthritis0.33
- Androgenetic alopecia0.27
- Nephrolithiasis0.24
- Response to statin0.21
- Hallux valgus0.20
- Immune system disorder0.15
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712898, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P18827, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets